Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D1.428 - Fungal Microbiome Diversity in Urban Forest Decreases Asthma and Allergic Inflammation
D1.431 - Associations of the composition of intestinal microbiota with the initial manifestations of IgE-mediated food allergy in children 6-12 months old
D1.433 - The effect of preventive administration of probiotic strain E. coli 083:H24:K31 on selected immune characteristics of eight-year-old children
D3.399 - Age-Dependent Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic esophagitis
D3.402 - Potential role of Advanced Glycation End-products in Pediatric Eosinophilic Esophagitis
D3.403 - Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study
D3.404 - Disease induction in a mouse model of eosinophilic esophagitis is lymphocyte dependent
D3.405 - Clinical Characteristics and Treatment Response of Eosinophilic Esophagitis in Pediatric Patients: A Descriptive Study from a High-Complexity Colombian Institution
D3.406 - Experience of dupilumab in difficult-to-treat eosinophilic esophagitis - A Case Series of 6 Portuguese Patients
D3.407 - Clinic-pathological characteristics and comorbidities in adult patients with eosinophilic esophagitis in Greece
D3.409 - Eosinophilic esophagitis and hen's egg tolerance: two cases highlighting remission with strongly heated but not less heated hen's egg despite topical steroid treatment
D3.410 - A concurrence of eosinophilic esophagitis and eosinophilic gastritis in a patient with hypereosinophillia
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download